Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

146 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis.
Elg M, Gustafsson D, Deinum J. Elg M, et al. Among authors: gustafsson d. Thromb Haemost. 1997 Oct;78(4):1286-92. Thromb Haemost. 1997. PMID: 9364999
Design, synthesis, and SAR of a series of activated protein C (APC) inhibitors with selectivity against thrombin for the treatment of haemophilia.
Bach P, Knerr L, Fjellström O, Hansson K, Mattsson C, Gustafsson D. Bach P, et al. Among authors: gustafsson d. Bioorg Med Chem Lett. 2014 Feb 1;24(3):821-7. doi: 10.1016/j.bmcl.2013.12.094. Epub 2013 Dec 29. Bioorg Med Chem Lett. 2014. PMID: 24418773
Discovery of ximelagatran in an historical perspective.
Gustafsson D. Gustafsson D. Semin Vasc Med. 2005 Aug;5(3):227-34. doi: 10.1055/s-2005-916161. Semin Vasc Med. 2005. PMID: 16123909 Review.
A combination of a thrombin inhibitor and dexamethasone prevents the development of experimental disseminated intravascular coagulation in rats.
Elg M, Gustafsson D. Elg M, et al. Among authors: gustafsson d. Thromb Res. 2006;117(4):429-37. doi: 10.1016/j.thromres.2005.03.014. Thromb Res. 2006. PMID: 15869787
A new oral anticoagulant: the 50-year challenge.
Gustafsson D, Bylund R, Antonsson T, Nilsson I, Nyström JE, Eriksson U, Bredberg U, Teger-Nilsson AC. Gustafsson D, et al. Nat Rev Drug Discov. 2004 Aug;3(8):649-59. doi: 10.1038/nrd1466. Nat Rev Drug Discov. 2004. PMID: 15286732 Review. No abstract available.
Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis.
Eriksson UG, Mandema JW, Karlsson MO, Frison L, Gisleskog PO, Wählby U, Hamrén B, Gustafsson D, Eriksson BI. Eriksson UG, et al. Among authors: gustafsson d. Clin Pharmacokinet. 2003;42(7):687-701. doi: 10.2165/00003088-200342070-00006. Clin Pharmacokinet. 2003. PMID: 12844328 Clinical Trial.
The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review.
Gustafsson D, Elg M. Gustafsson D, et al. Thromb Res. 2003 Jul 15;109 Suppl 1:S9-15. doi: 10.1016/s0049-3848(03)00249-4. Thromb Res. 2003. PMID: 12818629 Review.
Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects.
Eriksson UG, Bredberg U, Gislén K, Johansson LC, Frison L, Ahnoff M, Gustafsson D. Eriksson UG, et al. Among authors: gustafsson d. Eur J Clin Pharmacol. 2003 May;59(1):35-43. doi: 10.1007/s00228-003-0565-7. Epub 2003 Mar 27. Eur J Clin Pharmacol. 2003. PMID: 12743672 Clinical Trial.
No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteers.
Johansson LC, Andersson M, Fager G, Gustafsson D, Eriksson UG. Johansson LC, et al. Among authors: gustafsson d. Clin Pharmacokinet. 2003;42(5):475-84. doi: 10.2165/00003088-200342050-00005. Clin Pharmacokinet. 2003. PMID: 12739985 Clinical Trial.
Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
Johansson LC, Frison L, Logren U, Fager G, Gustafsson D, Eriksson UG. Johansson LC, et al. Among authors: gustafsson d. Clin Pharmacokinet. 2003;42(4):381-92. doi: 10.2165/00003088-200342040-00006. Clin Pharmacokinet. 2003. PMID: 12648028 Clinical Trial.
146 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback